Prevalence of Pterygium and Outcome of Pterygium Surgery in Hilly Western Nepal: A Hospital based Study

Authors

  • Laxmi Devi Manandhar Palpa Lions Lacoul Eye hospital, Lumbini Eye Institute
  • Salma KC Rai Shree Rana Ambika Shah Eye Hospital, Lumbini Eye institute
  • Shanti Gurung Shree Rana Ambika Shah Eye Hospital, Lumbini Eye institute
  • Koshal Shrestha Shree Rana Ambika Shah Eye Hospital, Lumbini Eye institute
  • Manita Godar Shree Rana Ambika Shah Eye Hospital, Lumbini Eye institute
  • Anjita Hirachan Shree Rana Ambika Shah Eye Hospital, Lumbini Eye institute
  • Ruchi Shrestha Reiyukai Eiko Masunaga Eye Hospital, Banepa, Kavre

Keywords:

Autograft, Conjunctiva, Prevalence, Pterygium, Recurrence

Abstract

Introduction: Surgical removal is the treatment of choice for pterygium; however, prevention of recurrence is a challenge. Several techniques have been tried to reduce the fibro-vascular activity aiming to reduce rate of recurrence such as B-irradiation, conjunctival and limbal auto-grafting, anti-mitotic drugs, and amniotic membrane transplantation. This study reports the magnitude of the disease in a hilly region of western Nepal and outcome of excision and conjunctival autografting for pterygium surgery.

Methods: A prospective study was done from 1st July 2015 to 31st December 2016 in which all patients with primary pterygium presented to Palpa Lions Lacoul Eye Hospital from 1st July 2015 to 30th June 2016 were treated and followed up for next six months. Patients were treated medically or surgically as indicated. Data on age, sex, visual acuity, extent of disease, treatment modality, complications, and outcome were collected and analyzed by descriptive statistics, Chi-square test, t-test, and Anova tests. P value less than 0.05 was considered significant.

Results: There were 18,960 patients in total attending hospital for various conditions among which 290 (1.53%) had pterygium. There were 186 (64.1%) female and 104 (35.9%) male and this difference was significant (p<0.001). The mean age was 47.42 yrs (SD=14.23) with age ranging from 20 to 80 years. Right eye was affected more (43.1%) than left eye (33.1%); remaining 23.8% had bilateral disease. Grade-1 disease occurred in younger age compared to Grade-2 and Grade-3 disease. All grade-1 patients were managed medically; grade-2 and grade-3 patients were equally likely to be managed medically or surgically. There were no major intra or post-operative complications. Minor post-operative complications noted were subconjunctival hemorrhage, corneal scarring, suture gaping, and conjunctival cyst among others.

Conclusion: Despite much advanced techniques in pterygium surgery, pterygium excision combined with conjunctival autograft is found to be a safe and effective method for treating pterygium in developing world.

Journal of Lumbini medical College

Vol 5, No 1, Jan-June 2017, page: 18-22

DOI: https://doi.org/10.22502/jlmc.v5i1.120

Downloads

Download data is not yet available.
Abstract
679
PDF
577

Downloads

Published

2017-07-05

How to Cite

Manandhar, L. D., Rai, S. K., Gurung, S., Shrestha, K., Godar, M., Hirachan, A., & Shrestha, R. (2017). Prevalence of Pterygium and Outcome of Pterygium Surgery in Hilly Western Nepal: A Hospital based Study. Journal of Lumbini Medical College, 5(1), 18–22. Retrieved from https://nepjol.info/index.php/JLMC/article/view/17681

Issue

Vol. 5 No. 1 (2017)

Section

Original Research Articles

License

The Journal of Lumbini Medical College (JLMC) publishes open access articles under the terms of the Creative Commons Attribution(CC BY) License which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

JLMC requires an exclusive licence allowing to publish the article in print and online.

The corresponding author should read and agree to the following statement before submission of the manuscript for publication,

License agreement
In submitting an article to Journal of Lumbini Medical College (JLMC) I certify that:

  1. I am authorized by my co-authors to enter into these arrangements.
  2. I warrant, on behalf of myself and my co-authors, that:
    • the article is original, has not been formally published in any other peer-reviewed journal, is not under consideration by any other journal and does not infringe any existing copyright or any other third party rights;
    • I am/we are the sole author(s) of the article and have full authority to enter into this agreement and in granting rights to JLMC are not in breach of any other obligation;
    • the article contains nothing that is unlawful, libellous, or which would, if published, constitute a breach of contract or of confidence or of commitment given to secrecy;
    • I/we have taken due care to ensure the integrity of the article. To my/our - and currently accepted scientific - knowledge all statements contained in it purporting to be facts are true and any formula or instruction contained in the article will not, if followed accurately, cause any injury, illness or damage to the user.
  3. I, and all co-authors, agree that the article, if editorially accepted for publication, shall be licensed under the Creative Commons Attribution License 4.0. If the law requires that the article be published in the public domain, I/we will notify JLMC at the time of submission, and in such cases the article shall be released under the Creative Commons 1.0 Public Domain Dedication waiver. For the avoidance of doubt it is stated that sections 1 and 2 of this license agreement shall apply and prevail regardless of whether the article is published under Creative Commons Attribution License 4.0 or the Creative Commons 1.0 Public Domain Dedication waiver.
  4. I, and all co-authors, agree that, if the article is editorially accepted for publication in JLMC, data included in the article shall be made available under the Creative Commons 1.0 Public Domain Dedication waiver, unless otherwise stated. For the avoidance of doubt it is stated that sections 1, 2, and 3 of this license agreement shall apply and prevail.

Please visit Creative Commons web page for details of the terms.